Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading Halt
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Apellis Pharmaceuticals Inc (APLS) – Apellis Pharmaceuticals Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Apellis Pharmaceuticals (APLS) trades at $41.03, matching its recent 52-week high following Biogen's $5.6 billion acquisition announcement at $41 per share. The stock's technical indicators signal a bullish trend, supported by a recent Q1 2026 earnings beat. Strong profitability metrics, including a 90.19% gross margin and 46.02% ROE, highlight operational efficiency, though valuation ratios like a P/E of 38.35 suggest a premium pricing relative to earnings.
The investment outlook is dominated by the pending acquisition, which provides a clear exit near the current price but limits upside. Key risks include shareholder litigation challenging the deal's fairness and integration execution post-acquisition. Analyst sentiment remains positive with a 70.83% buy rating, though the consensus price target of $34.70 implies potential downside if the deal encounters obstacles.
Read full analysis

Key Stats

  • Market Cap
    $5.25B
  • Sector
    Health
  • 3M Drawdown
    -24.48%
  • Enterprise Value
    $5.32B
  • Dividend Yield
    -
  • Typical Hold Time
    9 days
$41.04
52W Low: $16.8
28 May 2025
52W High: $41.12
06 May 2026

Apellis Pharmaceuticals Inc (APLS) is currently valued at a market capitalization of $5.25B, with an enterprise value of $5.32B. Over the past 52 weeks, Apellis Pharmaceuticals Inc has traded between a low of $16.8 and a high of $41.12, highlighting its annual price range. Over the past three months, Apellis Pharmaceuticals Inc has recorded a drawdown of -24.48%, reflecting recent price volatility. On average, investors hold Apellis Pharmaceuticals Inc for approximately 9 days, indicating typical investor behavior on the platform.

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is a biopharmaceutical company focused on complement science. It develops therapies for serious diseases, including the first-ever treatment for geographic atrophy, a leading cause of blindness.



People also bought


Global US Market Prices


Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Key Stats

  • Market Cap
    $5.25B
  • Sector
    Health
  • 3M Drawdown
    -24.48%
  • Enterprise Value
    $5.32B
  • Dividend Yield
    -
  • Typical Hold Time
    9 days
$41.04
52W Low: $16.8
28 May 2025
52W High: $41.12
06 May 2026

Apellis Pharmaceuticals Inc (APLS) is currently valued at a market capitalization of $5.25B, with an enterprise value of $5.32B. Over the past 52 weeks, Apellis Pharmaceuticals Inc has traded between a low of $16.8 and a high of $41.12, highlighting its annual price range. Over the past three months, Apellis Pharmaceuticals Inc has recorded a drawdown of -24.48%, reflecting recent price volatility. On average, investors hold Apellis Pharmaceuticals Inc for approximately 9 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!